Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.40 |
| ▸ | TYMP | P19971 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALB | P02768 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | TK2 | O00142 | 1/20 | 0.39 |
| ▸ | NT5M | Q9NPB1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23784803 | 1.00 | TK1 (0.44) | TK1HPGDRNASE1TYMPALDH1A1 | |
| SCHEMBL5696097 | 1.00 | TK1 (0.44) | TK1HPGDRNASE1TYMPALDH1A1 | |
| SCHEMBL5553146 | 1.00 | TK1 (0.44) | TK1HPGDRNASE1TYMPALDH1A1 | |
| SCHEMBL1096648 | 0.90 | TK1 (0.42) | TK1HPGDRNASE1TYMPALDH1A1 | |
| SCHEMBL1096225 | 0.90 | TK1 (0.42) | TK1HPGDRNASE1TYMPALDH1A1 | |
| SCHEMBL1096773 | 0.87 | RNASE1 (0.44) | TK1HPGDRNASE1TYMPALDH1A1 | |
| SCHEMBL5696095 | 0.87 | TK1 (0.40) | TK1HPGDRNASE1NT5M | |
| SCHEMBL5696090 | 0.87 | TK1 (0.40) | TK1HPGDRNASE1NT5M | |
| SCHEMBL2230414 | 0.87 | TK1 (0.40) | TK1HPGDRNASE1NT5M | |
| SCHEMBL23906525 | 0.86 | TK1 (0.41) | TK1HPGDRNASE1TYMPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1013661-B2 | 2'-O,4'-C-methylene bicyclonucleosides | EXIQON AS (DK) | 2018-10-24 | — | — | EP | disclosed |
| EP-2361921-B1 | Bicyclo-oligonucleotide analogues | EXIQON AS (DK) | 2015-06-03 | — | — | EP | disclosed |
| EP-2295441-B1 | Bicyclonucleoside Oligonucleotide Analogue | EXIQON AS (DK) | 2014-05-07 | — | — | EP | disclosed |
| US-RE44779-E1 | Bicyclonucleoside and oligonucleotide analogues | SANTARIS PHARMA A/S (DK) | 2014-02-25 | — | — | US | disclosed |
| EP-1013661-B1 | 2'-O,4'-C-methylene bicyclonucleosides | EXIQON AS (DK) | 2012-01-18 | — | — | EP | disclosed |
| EP-2361921-A2 | Novel bicyclonucleoside and oligonnucleotide analogue | Exiqon A/S (DK) | 2011-08-31 | — | — | EP | disclosed |
| EP-2295441-A2 | Novel Bicyclonucleoside and Oligonucleotide Analogue | Exiqon A/S (DK) | 2011-03-16 | — | — | EP | disclosed |
| EP-1163250-B1 | IMPROVED SYNTHESIS OF ¬2.2.1|BICYCLO NUCLEOSIDES | EXIQON AS (DK) | 2006-07-12 | — | — | EP | disclosed |
| US-6770748-B2 | ANTISENSE AGENTS FOR AIDS; IMMOBILIZED CONFORMATION OF THE SUGAR PORTION OF NUCLEIC ACID | Imanishi, Takeshi (JP) | 2004-08-03 | — | — | US | disclosed |
| US-6639059-B1 | Novel synthesis strategy comprising novel key intermediate, (2.2.1)bicyclo nucleosides are produced at least two steps shorter than any previously known strategy; 3-O-aryl-4-C-hydroxymethyl-1,2-O-isopropylidene-alpha-D-ribofuranose | EXIQON A/S (DK) | 2003-10-28 | — | — | US | disclosed |
| US-20030105309-A1 | Novel bicyclonucleoside and oligonucleotide analogue | TAKESHI IMANISHI (JP) | 2003-06-05 | — | — | US | disclosed |
| US-20030092905-A1 | Synthesis of [2.2.1]bicyclo nucleosides | EXIQON A/S | 2003-05-15 | — | — | US | disclosed |
| US-6268490-B1 | NUCLEOSIDE ANALOG; FOR ANTISENSE AGENT WHICH IS HYDROLASE RESISTANT, HAS HIGH SENSE STRAND BINDING ABILITY AND IS EASILY SYNTHESIZED | TAKESHI IMANISHI (JP) | 2001-07-31 | — | — | US | disclosed |
| EP-1013661-A1 | NOVEL BICYCLONUCLEOSIDE AND OLIGONUCLEOTIDE ANALOGUES | Imanishi, Takeshi (JP) | 2000-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105309-A1 | Novel bicyclonucleoside and oligonucleotide analogue | DCLRE1B, POLA1, POLB | TK1 16/4885HPGD 2958/4885RNASE1 6/4885 |
| US-20030092905-A1 | Synthesis of [2.2.1]bicyclo nucleosides | NSUN2, RNGTT, RNMT | TK1 72/4885HPGD 3399/4885RNASE1 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.